Esperion Gross Profit from 2010 to 2025

ESPR Stock

USD 1.69 0.07 4.32%

Esperion Therapeutics Gross Profit yearly trend continues to be relatively stable with very little volatility. Gross Profit is likely to drop to about 327.3 M. Gross Profit is the profit Esperion Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2000-03-31

Previous Quarter

34.3 M

Current Value

43.5 M

Quarterly Volatility

43.4 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Esperion Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Esperion Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.4 K, Interest Expense of 62.2 M or Gross Profit of 327.3 M, as well as many indicators such as Price To Sales Ratio of 1.18, Dividend Yield of 0.0 or Days Sales Outstanding of 84.78. Esperion financial statements analysis is a perfect complement when working with Esperion Therapeutics Valuation or Volatility modules.

Check out the analysis of Esperion Therapeutics Correlation against competitors.

To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.

Latest Esperion Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Esperion Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Esperion Therapeutics minus its cost of goods sold. It is profit before Esperion Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Esperion Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Esperion Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 217.48 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Esperion Gross Profit Regression Statistics

	Arithmetic Mean	1,000,661,898
	Geometric Mean	0.00
	Coefficient Of Variation	197.57
	Mean Deviation	1,491,131,288
	Median	73,067,000
	Standard Deviation	1,976,991,210
	Sample Variance	3908494.2T
	Range	5.1B
	R-Value	(0.54)
	Mean Square Error	2975265.5T
	R-Squared	0.29
	Significance	0.03
	Slope	(223,433,738)
	Total Sum of Squares	58627413.7T

Esperion Gross Profit History

	2025	327.3 M
	2024	332.3 M
	2023	73.1 M
	2022	48.5 M
	2021	64.2 M
	2020	225.2 M
	2019	-27.2 M

Other Fundumenentals of Esperion Therapeutics

Gross Profit Margin

Esperion Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Intangible Assets	Short Term Investments	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Capital Surpluse	Long Term Investments	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Net Receivables
Total Assets		-0.43	0.07	-0.59	0.51	0.55	0.98	0.21	0.41	-0.4	0.33	0.55	0.48	0.19	-0.3	0.77	0.47	0.61	0.58	-0.43	0.19	0.3	0.37
Total Stockholder Equity	-0.43		-0.24	0.68	-0.56	-0.67	-0.55	-0.29	-0.31	0.16	0.32	-0.83	-0.15	-0.3	0.75	-0.7	0.19	-0.7	-0.69	0.69	-0.07	-0.25	-0.3
Net Debt	0.07	-0.24		-0.68	0.29	0.67	0.13	0.73	0.66	-0.05	-0.3	0.61	-0.61	0.89	-0.71	0.51	0.14	0.37	0.62	-0.71	-0.6	0.68	0.72
Retained Earnings	-0.59	0.68	-0.68		-0.79	-0.97	-0.68	-0.79	-0.87	0.28	0.26	-0.96	0.13	-0.68	0.9	-0.91	-0.11	-0.86	-0.93	0.96	0.38	-0.82	-0.82
Accounts Payable	0.51	-0.56	0.29	-0.79		0.74	0.62	0.59	0.7	-0.25	-0.2	0.76	0.14	0.37	-0.63	0.73	-0.22	0.88	0.73	-0.77	-0.34	0.64	0.58
Total Liab	0.55	-0.67	0.67	-0.97	0.74		0.65	0.84	0.87	-0.22	-0.4	0.95	-0.14	0.64	-0.93	0.83	0.06	0.78	0.98	-0.91	-0.23	0.84	0.81
Total Current Assets	0.98	-0.55	0.13	-0.68	0.62	0.65		0.29	0.47	-0.39	0.21	0.66	0.45	0.26	-0.43	0.85	0.32	0.69	0.68	-0.55	0.13	0.36	0.45
Short Term Debt	0.21	-0.29	0.73	-0.79	0.59	0.84	0.29		0.94	-0.19	-0.45	0.69	-0.48	0.56	-0.79	0.55	0.03	0.52	0.79	-0.75	-0.46	0.97	0.9
Common Stock	0.41	-0.31	0.66	-0.87	0.7	0.87	0.47	0.94		-0.21	-0.28	0.75	-0.33	0.55	-0.75	0.67	0.15	0.65	0.81	-0.81	-0.49	0.99	0.91
Intangible Assets	-0.4	0.16	-0.05	0.28	-0.25	-0.22	-0.39	-0.19	-0.21		-0.18	-0.24	-0.16	-0.1	0.11	-0.33	-0.18	-0.29	-0.21	0.23	0.07	-0.14	-0.14
Short Term Investments	0.33	0.32	-0.3	0.26	-0.2	-0.4	0.21	-0.45	-0.28	-0.18		-0.35	0.27	-0.33	0.61	0.0	0.51	-0.08	-0.39	0.37	0.08	-0.36	-0.34
Long Term Debt	0.55	-0.83	0.61	-0.96	0.76	0.95	0.66	0.69	0.75	-0.24	-0.35		-0.05	0.63	-0.93	0.88	-0.01	0.84	0.94	-0.94	-0.24	0.7	0.7
Property Plant Equipment	0.48	-0.15	-0.61	0.13	0.14	-0.14	0.45	-0.48	-0.33	-0.16	0.27	-0.05		-0.29	0.3	0.08	0.03	0.09	-0.1	0.14	0.47	-0.42	-0.42
Current Deferred Revenue	0.19	-0.3	0.89	-0.68	0.37	0.64	0.26	0.56	0.55	-0.1	-0.33	0.63	-0.29		-0.67	0.59	0.1	0.44	0.58	-0.76	-0.58	0.54	0.64
Net Tangible Assets	-0.3	0.75	-0.71	0.9	-0.63	-0.93	-0.43	-0.79	-0.75	0.11	0.61	-0.93	0.3	-0.67		-0.73	0.14	-0.68	-0.91	0.9	0.28	-0.75	-0.76
Capital Surpluse	0.77	-0.7	0.51	-0.91	0.73	0.83	0.85	0.55	0.67	-0.33	0.0	0.88	0.08	0.59	-0.73		0.25	0.87	0.81	-0.85	-0.28	0.59	0.71
Long Term Investments	0.47	0.19	0.14	-0.11	-0.22	0.06	0.32	0.03	0.15	-0.18	0.51	-0.01	0.03	0.1	0.14	0.25		0.07	0.01	0.0	0.02	0.1	0.14
Long Term Debt Total	0.61	-0.7	0.37	-0.86	0.88	0.78	0.69	0.52	0.65	-0.29	-0.08	0.84	0.09	0.44	-0.68	0.87	0.07		0.74	-0.81	-0.26	0.57	0.55
Short Long Term Debt	0.58	-0.69	0.62	-0.93	0.73	0.98	0.68	0.79	0.81	-0.21	-0.39	0.94	-0.1	0.58	-0.91	0.81	0.01	0.74		-0.85	-0.11	0.77	0.75
Net Invested Capital	-0.43	0.69	-0.71	0.96	-0.77	-0.91	-0.55	-0.75	-0.81	0.23	0.37	-0.94	0.14	-0.76	0.9	-0.85	0.0	-0.81	-0.85		0.52	-0.76	-0.78
Net Working Capital	0.19	-0.07	-0.6	0.38	-0.34	-0.23	0.13	-0.46	-0.49	0.07	0.08	-0.24	0.47	-0.58	0.28	-0.28	0.02	-0.26	-0.11	0.52		-0.5	-0.54
Capital Stock	0.3	-0.25	0.68	-0.82	0.64	0.84	0.36	0.97	0.99	-0.14	-0.36	0.7	-0.42	0.54	-0.75	0.59	0.1	0.57	0.77	-0.76	-0.5		0.92
Net Receivables	0.37	-0.3	0.72	-0.82	0.58	0.81	0.45	0.9	0.91	-0.14	-0.34	0.7	-0.42	0.64	-0.76	0.71	0.14	0.55	0.75	-0.78	-0.54	0.92

Click cells to compare fundamentals

About Esperion Therapeutics Financial Statements

Esperion Therapeutics shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although Esperion Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Esperion Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Esperion Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	332.3 M	327.3 M
Gross Profit Margin	0.57	0.52

Pair Trading with Esperion Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Esperion Stock

0.78	CDIOW	Cardio Diagnostics	Pair Corr
0.75	ELVN	Enliven Therapeutics	Pair Corr

Moving against Esperion Stock

0.86	WM	Waste Management	Pair Corr
0.82	LUCD	Lucid Diagnostics	Pair Corr
0.78	GE	GE Aerospace	Pair Corr
0.61	PG	Procter Gamble	Pair Corr
0.58	PLX	Protalix Biotherapeutics	Pair Corr

The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.

The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Esperion Stock Analysis

When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC